At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Single-center, Randomized, Placebo- and Positive-controlled, Parallel-group Trial With a Nested Crossover Part on the Electrocardiographic Effects 100 and 400 mg Pritelivir Per Day in Healthy Subjects: a Thorough QT/QTc Trial
In Brief
A Phase 1 clinical trial evaluating Pritelivir and moxifloxacin placebo, Pritelivir placebo, moxifloxacin and moxifloxacin placebo, and 1 other intervention for Healthy Subjects. Completed, enrolled 64 participants across 1 site.
Detailed Summary
This Phase 1 clinical trial was a double-blind, single-center, randomized and placebo-controlled trial in which healthy male and female subjects received in 2 parallel-groups daily oral doses of pritelivir (Group 1) or matching placebo (Group 2). Within Group 2, a single oral administration of moxifloxacin (positive control) and corresponding matching placebo was administered in a 2-sequence crossover design (nested crossover).
Study Details
Timeline
Interventions
oral administration
oral administration
oral administration